Drug Trial Radar · NCT06642961
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma
Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Planned (sponsor's estimate)
Start
Jul 19, 2022
Primary completion
Mar 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of GR1802 injection in comparison to placebo in patients with atopic dermatitis. Patients will receive GR1802 injection or Placebo every 2 Weeks.
Conditions
- Asthma
Interventions
GR1802 injectionDrug
GR1802 will be administered SC.
GR1802 injectionDrug
GR1802 will be administered SC.
PlaceboOther
The placebo will be administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in pre-bronchodilator FEV1 (forced expiratory volume in 1 second) at 12 weeks.Time frame: 12weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.